SCHEMBL5447128

SCHEMBL5447128

NC(=O)c1c(NC(=O)c2ccc(C=S)cc2)sc2c(Cl)c(O)ccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 10/20 0.42
GRIN2C Q14957 1/20 0.38
NPC1 O15118 7/20 0.36
RAB9A P51151 7/20 0.36
CDC7 O00311 1/20 0.36
PLK4 O00444 1/20 0.36
DYRK3 O43781 1/20 0.36
ROCK2 O75116 1/20 0.36
PRKD3 O94806 1/20 0.36
MAP4K4 O95819 1/20 0.36
PRKCG P05129 1/20 0.36
INSR P06213 1/20 0.36
CDK1 P06493 1/20 0.36
PIM1 P11309 1/20 0.36
FGFR1 P11362 1/20 0.36
FER P16591 1/20 0.36
PRKACA P17612 1/20 0.36
RPS6KB1 P23443 1/20 0.36
CDK2 P24941 1/20 0.36
KDR P35968 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5456366 0.89 FLT3 (0.52) FLT3GRIN2CNPC1RAB9ACDC7
SCHEMBL5447561 0.84 FLT3 (0.43) FLT3GRIN2CNPC1RAB9ACDC7
SCHEMBL5460181 0.83 GRIN2C (0.44) FLT3GRIN2CNPC1RAB9ACDC7
SCHEMBL5466113 0.83 FLT3 (0.42) FLT3GRIN2CNPC1RAB9AMEN1
SCHEMBL5447136 0.83 FLT3 (0.44) FLT3GRIN2CNPC1RAB9ACDC7
SCHEMBL5460130 0.83 FLT3 (0.42) FLT3GRIN2CNPC1RAB9ACDC7
SCHEMBL5455924 0.80 FLT3 (0.54) FLT3GRIN2CNPC1RAB9AMEN1
SCHEMBL5453155 0.80 TAS1R3 (0.43) FLT3NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL5458431 0.77 FLT3 (0.45) FLT3NPC1RAB9AMEN1KMT2A
SCHEMBL5450952 0.77 RHOC (0.42) FLT3GRIN2CKDRMAP4K5MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885GRIN2C 427/4885NPC1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.